Skip to content 
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida. more
| Time Frame | PCSA | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -0.71% | 2.09% | 3.19% |
| 1-Month Return | -4.79% | -2.49% | 0.37% |
| 3-Month Return | -11.46% | -5.12% | -2.24% |
| 6-Month Return | -70.66% | 5.08% | 4.08% |
| 1-Year Return | -57.23% | 10.71% | 29.66% |
| 3-Year Return | -98.89% | 11.92% | 66.07% |
| 5-Year Return | -99.95% | 26.48% | 65.17% |
| 10-Year Return | -99.93% | 116.99% | 234.09% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Cost of Revenue | 875.35K | 874.01K | 222.00 | 782.00 | 1.20K | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.85,"profit":true},{"date":"2023-12-31","value":0.03,"profit":true},{"date":"2024-12-31","value":0.09,"profit":true},{"date":"2025-12-31","value":0.14,"profit":true}] |
| Gross Profit | (875.35K) | (874.01K) | (222.00) | (782.00) | (1.20K) | [{"date":"2021-12-31","value":-87534900,"profit":false},{"date":"2022-12-31","value":-87401300,"profit":false},{"date":"2023-12-31","value":-22200,"profit":false},{"date":"2024-12-31","value":-78200,"profit":false},{"date":"2025-12-31","value":-120400,"profit":false}] |
| Gross Margin | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Operating Expenses | 12.13M | 27.53M | 11.46M | 12.05M | 13.99M | [{"date":"2021-12-31","value":44.08,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.62,"profit":true},{"date":"2024-12-31","value":43.78,"profit":true},{"date":"2025-12-31","value":50.82,"profit":true}] |
| Operating Income | (12.13M) | (27.53M) | (11.46M) | (12.05M) | (13.99M) | [{"date":"2021-12-31","value":-1213354300,"profit":false},{"date":"2022-12-31","value":-2752543100,"profit":false},{"date":"2023-12-31","value":-1145706100,"profit":false},{"date":"2024-12-31","value":-1205120600,"profit":false},{"date":"2025-12-31","value":-1398850500,"profit":false}] |
| Total Non-Operating Income/Expense | 187.03K | 202.40K | 662.09K | 402.18K | 534.16K | [{"date":"2021-12-31","value":28.25,"profit":true},{"date":"2022-12-31","value":30.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":60.74,"profit":true},{"date":"2025-12-31","value":80.68,"profit":true}] |
| Pre-Tax Income | (11.96M) | (27.42M) | (11.12M) | (11.85M) | (13.56M) | [{"date":"2021-12-31","value":-1195814500,"profit":false},{"date":"2022-12-31","value":-2742422900,"profit":false},{"date":"2023-12-31","value":-1112152000,"profit":false},{"date":"2024-12-31","value":-1185011800,"profit":false},{"date":"2025-12-31","value":-1356383400,"profit":false}] |
| Income Taxes | (530.61K) | 27.42M | (2.00) | - | - | [{"date":"2021-12-31","value":-1.93,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income After Taxes | (11.43M) | (54.85M) | (11.12M) | - | - | [{"date":"2021-12-31","value":-1142753400,"profit":false},{"date":"2022-12-31","value":-5484822900,"profit":false},{"date":"2023-12-31","value":-1112151800,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (11.43M) | (27.42M) | (21.73M) | (11.85M) | (13.56M) | [{"date":"2021-12-31","value":-1142753400,"profit":false},{"date":"2022-12-31","value":-2742422900,"profit":false},{"date":"2023-12-31","value":-2172890900,"profit":false},{"date":"2024-12-31","value":-1185011800,"profit":false},{"date":"2025-12-31","value":-1356383400,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (11.43M) | (27.42M) | (11.12M) | (11.85M) | (13.56M) | [{"date":"2021-12-31","value":-1142753400,"profit":false},{"date":"2022-12-31","value":-2742422900,"profit":false},{"date":"2023-12-31","value":-1112152000,"profit":false},{"date":"2024-12-31","value":-1185011800,"profit":false},{"date":"2025-12-31","value":-1356383400,"profit":false}] |
| EPS (Diluted) | (0.74) | (1.25) | (2.06) | (3.89) | - | [{"date":"2021-12-31","value":-74,"profit":false},{"date":"2022-12-31","value":-125,"profit":false},{"date":"2023-12-31","value":-205.7,"profit":false},{"date":"2024-12-31","value":-389,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| PCSA | |
|---|---|
| Cash Ratio | 2.48 |
| Current Ratio | 2.54 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| PCSA | |
|---|---|
| ROA (LTM) | -158.34% |
| ROE (LTM) | -372.97% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| PCSA | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.29 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.71 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| PCSA | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 1320.06 |
| P/B | 1.44 |
| Price/FCF | NM |
| EV/R | 68.28 |
| EV/Ebitda | NM |
Processa Pharmaceuticals Inc (PCSA) share price today is $2.77
Yes, Indians can buy shares of Processa Pharmaceuticals Inc (PCSA) on Vested. To buy
Yes, you can purchase fractional shares of Processa Pharmaceuticals Inc (PCSA) via the Vested app. You can start investing in Processa Pharmaceuticals Inc (PCSA) with a minimum investment of $1.
You can invest in shares of Processa Pharmaceuticals Inc (PCSA) via Vested in three simple steps:
The 52-week high price of Processa Pharmaceuticals Inc (PCSA) is $19.63. The 52-week low price of Processa Pharmaceuticals Inc (PCSA) is $1.76.
The price-to-earnings (P/E) ratio of Processa Pharmaceuticals Inc (PCSA) is
The price-to-book (P/B) ratio of Processa Pharmaceuticals Inc (PCSA) is 1.44
The dividend yield of Processa Pharmaceuticals Inc (PCSA) is 0.00%
The market capitalization of Processa Pharmaceuticals Inc (PCSA) is $7.90M
The stock symbol (or ticker) of Processa Pharmaceuticals Inc is PCSA
Consider the share price of Processa Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Processa Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Processa Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Processa Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Processa Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Processa Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
